Charles River Laboratories Intl. Inc vs Enphase Energy Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $228.24 (market cap $11.14B), while Enphase Energy Inc trades at $43.68 (market cap $5.93B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Enphase Energy Inc nearer its low. Which is the better fit depends on your goals.
| CRL | ENPH | |
|---|---|---|
Market Cap | $11.14B | $5.93B |
Sector | Health | Technology |
52-Week High | $233.60 | $72.33 |
52-Week Low | $145.57 | $26.12 |
Enterprise Value | $14.00B | $5.58B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Enphase Energy (ENPH) trades at $43.06, down 3.95% on the day, near its consensus price target of $42.79. The stock shows a bearish technical signal with declining cash flows and mixed earnings trends, though recent quarters have beaten estimates. Recent news includes product expansions in Australia and New Zealand and involvement in AI data center power standards, providing some positive catalysts amid overall market caution.
Outlook remains cautious with high valuation ratios (P/E 44.39) pressuring upside, while analyst sentiment is divided (40% Buy, 51% Hold). Key risks include competitive pressures and volatile solar demand, but institutional interest and strategic initiatives offer potential for recovery if execution improves.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →